"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin B 3
- B 3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Vitamin B3
- B3, Vitamin
- Nicotinamide
- Vitamin PP
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
-
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clin Cancer Res. 2017 Aug 15; 23(16):4633-4641.
-
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol. 2017 04; 12(2):201-209.
-
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016 Jan; 113(1):55-61.
-
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLoS One. 2015; 10(9):e0139237.
-
Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014 Nov; 60(5):1637-44.
-
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology. 2013 Nov; 58(5):1655-66.
-
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
-
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012 Sep 15; 18(18):4997-5007.
-
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012 Jun; 56(6):1343-50.